OphtAI Revenue

About OphtAI

OphtAI, an Artificial Intelligence which, by analysing retina fundus photos in a few seconds, is able to detect early signs of Diabetic Retinopathy as well as the risk of Glaucoma or AMD. 425 million diabetics in the world, forecast to grow up to 600 million in 2035. ~30% of them would have diabetic retinopathy. This retina disease is the 1st cause of blindness in people under 60 years old. Hence, its screening is a public health issue and must be systematic: the WHO recommends if for all diabetics once a year. OphtAI answers a public healthcare need and aims for massive-automated eye disease screening. It meets a major challenge: the management of all patients at risk of eye disease and, therefore, eye care organization optimization. Ophthalmologists practicing fundus with pupil dilation cannot be the only solution for this. A first line that will sort out patients at risk and send only them for being managed is needed. This increases screening capacity while saving medical time. Different organizations are possible depending on local state regulations. Operators who take retinal photos with a non-mydriatic retinograph screens themselves or send photos for remote interpretation. In both cases, OphtAI use allows for photo quality control, lesion mapping, pathology severity level assessment and recommends the course of action to take. This can be accessed directly on the Internet using the my.ophtAI.com website or integrated into our partners' software packages and instruments. Our service, which is a CE Cat IIa medical device, guarantees the same screening quality as the best retinologists and can therefore be used by non-experts during patient consultation. It was developed in partnership with the Paris Hospitals (AP-HP), France's largest screening network, and an INSERM research laboratory specialized in AI. The -already patented- next version of OphtAI will be able to detect some 40 pathological signs and symptoms in the general population

View contact profiles from OphtAI